Anastrozole
SIGMA/A2736 - ≥98% (HPLC)
Synonym: 2;2"-
CAS Number: 120511-73-1
Empirical Formula (Hill Notation): C17H19N5
Molecular Weight: 293.37
Linear Formula: C17H19N5
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | solid |
| InChI | 1S/C17H19N5/c1-16(2,9-18) |
| InChI key | YBBLVLTVTVSKRW-UHFFFAOYSA |
| originator | AstraZeneca |
| Quality Level | 100  |
| solubility | DMSO: 40 mg/mL |
| storage temp. | room temp |
| Application: | Anastrozole (aromatase inhibitor) has been used: • as a positive control in DNA fragmentation (ladder) assay • to investigate its effects along with extra virgin olive oil and its major fatty acid component (omega-9 OA) in estrogen receptor positive mammary adenocarcinoma cells • to study its effects on viability, cell proliferation and apoptosis in Glioblastoma multiforme model in vivo |
| Biochem/physiol Actions: | Anastrozole, which contains a triazole functional group, reversibly binds to the cytochrome P-450 component of aromatase. Binding interferes with the catalytic properties of aromatase, which results in inhibition of estrogen synthesis. |
| Biochem/physiol Actions: | The aromatase enzyme converts adrenal androgens to estrogen; this enzymatic activity is the primary source of estrogen production in postmenopausal women. One treatment for estrogen receptor-positive breast cancer in postmenopausal women is through inhibition of aromatase. Anastrozole is a nonsteroidal, benzyl-triazole derivative that inhibits aromatase through competitive inhibition and is used to treat estrogen receptor-positive breast cancer. This compound is considered a third-generation, Type II aromatase inhibitor because it is more selective and less effective (if at all) on other steroidal hormones than first and second generation inhibitors. |
| Features and Benefits: | This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by AstraZeneca . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |   GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H302 - H360 |
| Precautionary statements | P201 - P301 + P312 + P330 - P308 + P313 |
| Hazard Codes | Xn |
| Risk Statements | 60-61-22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 51111800 |